SEC Comment Letter for Liminal BioSciences Inc. (CIK 0001351172) — Dec 7, 2020
Liminal BioSciences Inc. (CIK 0001351172)
Date: Dec. 7, 2020 · CIK: 0001351172 · Accession: 0000000000-20-011713
AI Filing Summary & Sentiment
File numbers found in text: 333-251055
Letter
United States securities and exchange commission logo December 7, 2020 Murielle Lortie Chief Financial Officer Liminal BioSciences Inc. 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 Re:Liminal BioSciences Inc. Registration Statement on Form F-3 Filed December 1, 2020 File No. 333-251055 Dear Ms. Lortie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jaime L. Chase, Esq.
Show Raw Text
United States securities and exchange commission logo
December 7, 2020
Murielle Lortie
Chief Financial Officer
Liminal BioSciences Inc.
440 Armand-Frappier Boulevard, Suite 300
Laval, Québec H7V 4B4
Re:Liminal BioSciences Inc.
Registration Statement on Form F-3
Filed December 1, 2020
File No. 333-251055
Dear Ms. Lortie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jaime L. Chase, Esq.